A Double-Blinded, Placebo Controlled, Single Ascending Dose Study for Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics after Subcutaneous Administration of Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in Healthy Obese Subjects

被引：6
|
作者：
Choi, Jae Duk
Baek, Seungjae
Kim, Youngmin
Eun, Kahee
Kwon, Se Chang
Morrow, Linda
Hompesch, Marcus
Kang, Jahoon
机构：
来源：
DIABETES | 2019年 / 68卷
关键词：
D O I：
10.2337/db19-982-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
982-P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist (HM15211) in animal model of NASH
    Choi, J.
    Lee, J.
    Kim, J.
    Kwon, H.
    Park, E.
    Lee, J.
    Kim, D.
    Kim, Y.
    Choi, I.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 100 - 101
  • [22] Antifibrotic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in BDL-Induced Liver Fibrosis Mice
    Kim, Jung Kuk
    Lee, Jong Suk
    Kwon, Hyunjoo
    Lee, Jongsoo
    Kim, Daejin
    Bae, Sungmin
    Lee, Sang Hyun
    Choi, In Young
    DIABETES, 2020, 69
  • [23] STUDY ON MULTI-TARGET ENGAGEMENT EFFECT OF A NOVEL LONG-ACTING GLUCAGON/GIP/GLP-1 TRIPLE AGONIST, HM15211, IN ANIMAL MODEL OF NASH
    Lee, Jong Suk
    Kim, Jung Kuk
    Lee, Seon Myeong
    Choi, Jaehyuk
    Kwon, Hyunjoo
    Park, Eun Jin
    Lee, Jong Soo
    Kim, Dae Jin
    Lee, Sang Hyun
    Choi, In Young
    HEPATOLOGY, 2021, 74 : 1088A - 1089A
  • [24] Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in CDHFD-Induced NASH and Fibrosis Mice
    Choi, Jaehyuk
    Kim, Jung Kuk
    Lee, Seon Myeong
    Kwon, Hyunjoo
    Lee, Jongsoo
    Bae, Sungmin
    Kim, Daejin
    Choi, In Young
    DIABETES, 2020, 69
  • [25] Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of the Novel Dual GIP/GLP-1 Agonist (RG7697) after Single Subcutaneous Administration in Healthy Subjects
    Portron, Agnes
    Jadidi, Shirin
    Sarkar, Neena
    Dimarchi, Richard
    Schmitt, Christophe
    DIABETES, 2017, 66 : A624 - A624
  • [26] A Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136, a Novel Long-Acting Glucagon Analogue, in Healthy Subjects
    Huh, Ki Young
    Shin, Wonjung
    Baek, Eunhye
    Seo, Sujin
    Lee, Woosun
    Baek, Seungjae
    Lee, Howard
    DIABETES, 2020, 69
  • [27] Anti-fibrotic potential of a novel long-acting Glucagon/GIP/GLP-1 triple agonist (HM15211) in preclinical models of idiopathic pulmonary fibrosis
    Lee, S.
    Kim, J.
    Lee, J.
    Kim, J.
    Ban, Y. -H.
    Lee, J.
    Bae, S.
    Kim, D.
    Lee, S.
    Choi, I.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S431 - S431
  • [28] Multi-target engagement effect of a novel long-acting Glucagon/GIP/GLP-1 triple agonist, HM15211, in animal model of NASH/fibrosis
    Lee, Jong Suk
    Kim, Jung Kuk
    Lee, Seonmyeong
    Kim, Yohan
    Choi, Jaehyuk
    Kwon, Hyunjoo
    Park, Eun Jin
    Bae, Sung Min
    Lee, Sang Hyun
    Choi, In Young
    JOURNAL OF HEPATOLOGY, 2022, 77 : S468 - S469
  • [29] Anti-fibrotic Potential of a Novel Long-acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of Idiopathic Pulmonary Fibrosis
    Kim, J.
    Kim, W.
    Lee, S.
    Lee, J.
    Kim, J.
    Bae, S.
    Kim, D.
    Lee, S.
    Choi, I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [30] A double-blind, placebo-controlled, single-ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM15136, a novel long-acting glucagon analogue, in healthy subjects
    Huh, Ki Young
    Hwang, Jun Gi
    Shin, Wonjung
    Baek, Seungjae
    Choi, JaeDuk
    Lee, Nora
    Cho, Young Min
    Lee, Howard
    DIABETES OBESITY & METABOLISM, 2022, 24 (03): : 411 - 420
12345